News

Get the latest on BIO's announcements, positions and views on everything from healthcare to biofuels.

Press Releases

Sylvia Wulf to Serve as Interim Lead of BIO's…

WASHINGTON, D.C., July 25, 2024—Today, the Biotechnology Innovation Organization (BIO) announced the appointment of longtime biotechnology executive Sylvia Wulf to lead the Agriculture & Environment Center of Excellence (AECOE). The AECOE…

Learn more

BIO Commends FDA Plan to Establish a Rare Disease…

July 17, 2024 – BIO President and CEO John F. Crowley today released the following statement after the U.S. Food & Drug Administration (FDA) announced a plan to establish a Rare Disease Innovation Hub that will utilize new and collaborative…

Learn more

BIO Applauds Introduction of Bipartisan…

BIO President and CEO John F. Crowley today released the following statement after a bipartisan group of Senators, Sen. Bob Casey (D-PA), Sen. Markwayne Mullin (R-OK), Sen. Sherrod Brown (D-OH), and Sen. Susan Collins (R-ME), introduced the Creating…

Learn more

Letters, Testimony, & Comments

Browse All

BIO Comments to the USPTO’s MAY 10, 2024 Proposed…

BIO submitted these comments in response to the United States Patent and Trademark Office’s May 10, 2024, Notice of Proposed Rulemaking regarding Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting.

Learn more

Comments of the Biotechnology Innovation…

On behalf of its member organizations, Biotechnology Innovation Organization (“BIO”) respectfully submits this Comment in response to the United States Patent and Trademark Office’s (the “Patent Office” or “PTO”) February 13, 2024 Request for…

Learn more

BIO Comments to FWS on Use of GMOs on National…

BIO comments on a proposed rule to restrict planting of GE organisms on national wildlife refuge lands.

Learn more

Amicus Briefs

Browse All

BIO FILES AMICUS BRIEF CHALLENGING FTC’S…

The Biotechnology Innovation Organization (BIO) today signed onto an amicus brief to challenge the Federal Trade Commission (FTC) lawsuit to block the acquisition of Horizon by Amgen. The amicus brief was filed in the U.S. District Court, Northern…

Learn more

BIO Files Amicus Brief in U.S. ex rel. Scutte v…

BIO has filed an amicus brief in U.S. ex rel. Scutte v. SuperValu Inc., which addresses the issue of the intent requirement under the False Claims Act (FCA). Specifically, BIO urges the Court to uphold the view that a firm does not…

Learn more

BIO JOINS AMICUS BRIEF CHALLENGING COURT’S…

The Biotechnology Innovation Organization (BIO) today signed onto an amicus brief to challenge a District Court’s unprecedented ruling (related to a single drug known as mifepristone) that would create regulatory barriers and potentially upend FDA’s…

Learn more